ArticleAnnals of translational medicine2015
The multiple facets of alpha-1-antitrypsin.
Article in Annals of translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 55 citations in OpenAlex.
- Geriatric respiratory medicine 2026: from artificial intelligence to personalised management of the multimorbid patient.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Scaled up fed-batch production of recombinant alpha-1-antitrypsin by CHO cells in single-use surface aerated orbital shaken bioreactor.Scientific reports · 2026Article
- Characteristics of bronchiectasis in patients with different genotypes of severe αERJ open research · 2026Article
- Oxidation-dependent effects of alpha-1 antitrypsin on wound healing and inflammation.Scientific reports · 2025Article
- α‑1 Antitrypsin is a potential target of inflammation and immunomodulation (Review).Molecular medicine reports · 2025Review
- Proteomics Analysis of Plasma-Derived Exosomes Unveils the Aberrant Complement and Coagulation Cascades in Dermatomyositis/Polymyositis.Journal of proteome research · 2023Article
- Placental proteome in late‑onset of fetal growth restriction.Molecular medicine reports · 2022Article
- Alpha-1 Antitrypsin Inhibits Tumorigenesis and Progression of Colitis-Associated Colon Cancer through Suppression of Inflammatory Neutrophil-Activated Serine Proteases and IGFBP-3 Proteolysis.International journal of molecular sciences · 2022Article
- Imbalance between alpha-1-antitrypsin and interleukin 6 is associated with in-hospital mortality and thrombosis during COVID-19.Biochimie · 2022Article
- Elastin turnover in ocular diseases: A special focus on age-related macular degeneration.Experimental eye research · 2022Review
- Liver-directedMolecular therapy. Methods & clinical development · 2022Article
- Observational
- Serum alpha-1-antitrypsin level in the severity prognosis of systemic lupus erythematosus patients: Systematic exploration of novel biomarker.BioMedicine · 2022Article
- Stimuli-responsive polypeptide nanogels for trypsin inhibition.Beilstein journal of nanotechnology · 2022Article
- Article
- Insights into the potential role of alpha1-antitrypsin in COVID-19 patients: Mechanisms, current update, and future perspectives.The clinical respiratory journal · 2021Article
- Therapeutic benefits of recombinant alpha1-antitrypsin IgG1 Fc-fusion protein in experimental emphysema.Respiratory research · 2021Article
- Patient Acceptance of Routine Serial Postoperative Endoscopy Following Low Anterior Resection (LAR) and Its Ability to Detect Biomarkers in Anastomotic Lavage Fluid.World journal of surgery · 2021Article
- Identification of Fucosylated SERPINA1 as a Novel Plasma Marker for Pancreatic Cancer Using Lectin Affinity Capture Coupled with iTRAQ-Based Quantitative Glycoproteomics.International journal of molecular sciences · 2021Article
- Trypsin-Like Proteases and Their Role in Muco-Obstructive Lung Diseases.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-1-antitrypsin (AAT) is recognised as a potent inhibitor of serine proteinases. Genetic deficiency is associated with several neutrophilic diseases including severe emphysema. This is believed to reflect the loss of inhibition of neutrophilic serine proteinases that then result in local tissue damage (the proteinase/antiprotease hypothesis). In recent years the role of AAT in the control of inflammatory and immunological processes has become identified. Although in some instances this may reflect its ability to control pro-inflammatory effects of serine proteinases it has also become recognised that it has non proteolytic mediated functions. This poly functional role is starting to become recognised offering a possibility of its use as a therapeutic agent in many clinical disease areas. The current review explores both the traditional and non-traditional function of AAT through published literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.